Sebastian Gensior

Valuing a biotech venture is a bit like valuing a promising but precarious alchemical experiment – full of potential magic, but with plenty of risk and uncertainty. Founders often see a blockbuster cure in the making, while investors see a long, expensive road with many potholes. The result can be wildly

Avalyn Pharma represents a compelling yet high-risk opportunity in the rapidly evolving pulmonary fibrosis therapeutics market. The company's differentiated approach of reformulating proven oral antifibrotics into inhaled formulations addresses critical tolerability limitations that plague current standard-of-care treatments. With a recently completed $100 million Series D

Tang Capital's contrarian strategy targets the 300 "zombie" companies holding $30 billion in trapped capital In the wreckage of biotech's 2021 bubble, where 300 companies now trade below their cash values and hold over $30 billion in trapped capital, Kevin Tang has built what

Overview of Digital Therapeutics and Reimbursement Digital therapeutics (DTx) are evidence-based software interventions prescribed to treat or manage medical conditions. As these “apps-as-medicine” gain regulatory approvals, reimbursement models have emerged as a key factor in their adoption. Governments and insurers in Europe and Asia have begun implementing

In January 2025, a long-awaited experiment in European healthcare quietly began. For the first time, all EU countries have started pooling their efforts to evaluate new medicines under a single framework. Historically, a cancer drug approved in Europe might reach patients in Germany within four months but take over

Advances in artificial intelligence (AI) are rapidly transforming drug development and clinical trials. Medicines regulatory agencies worldwide have responded by issuing guidance, strategic plans, and holding stakeholder engagements to ensure AI is used safely and effectively in the development of new therapies. This report reviews how major agencies – the U.

During the week of July 21–25, 2025, the biopharmaceutical industry saw a flurry of deal-making worldwide. This included major M&A acquisitions, high-value licensing and co-development partnerships, venture capital financings, and even an IPO listing. North America accounted for the majority of deal activity, with

Most biotech professionals are familiar with science and R&D, but deal press releases often include financial jargon that can be confusing. In this explainer, we’ll break down common finance terms and concepts relevant to pharma/biotech deal structuring – equity vs. debt financing, senior notes, covenants, debt preferences

Disclaimer: This analysis represents an opinion based on publicly available information and should not be considered investment advice. Please conduct your own research and consult a qualified financial advisor before making investment decisions. Strategic Refocus Extends Runway and Undervalues Pipeline Repare Therapeutics (NASDAQ: RPTX) underwent a dramatic strategic pivot in

BioPharma Credit PLC (BPCR) is a London-listed investment trust specializing in debt financing for the life sciences sector. Managed by Pharmakon Advisors, it provides loans to pharmaceutical and biotech companies with marketed drugs, aiming for an 8–9% annual net return on NAV and paying a steady $0.07